


AMENDMENTS TO THE CLAIMS


This listing of claims will replace all prior versions, and listings, of claims in the Application. Deletions are ~~strike through~~ and additions are underlined.


1 - 3. (Canceled)

4. (Currently amended) A pharmaceutical composition comprising; a compound ~~to treat cancer disease~~ represented by the following general formula (III), and ~~the~~ a pharmaceutically acceptable salt or ~~the~~ an isomer thereof:



wherein

X is selected from the group consisting of a hydroxyl group, -NHOH, -NHOCH₂Ph,  and



R is selected from the group consisting of a ~~lower C1-C5 alkyl group~~, ~~lower C2-C5 alkenyl group~~, ~~lower C2-C5 alkynyl group~~, ~~lower C3-C5 allyl group~~ having C1 to C5 carbon atoms, a heterocyclic group and aromatic aryl group;

n is an integer of 1 to 5; and

dotted line (---) means double bond.

5. (Previously presented) The pharmaceutical composition of claim 4, wherein said R is selected from the group consisting of thiophenyl group, naphthyl group, pyrrolyl group, furyl group and biphenyl group.

6. (Previously presented) The pharmaceutical composition of claim 5, wherein said compound is selected from the group consisting of;


N-hydroxy-3-(1-naphthalene-2-ylmethyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-propionamide,
N-hydroxy-3-(1-methyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-propionamide,
3-(1-allyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-N-hydroxy-propionamide,
N-hydroxy-3-[1-(2-naphthalene-1-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,
N-hydroxy-3-[1-(2-naphthalene-2-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,
N-hydroxy-3-[2-oxo-1-(2-thiophen-2-yl-ethyl)-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,
3-[1-(3-biphenyl-4-yl-propyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-N-hydroxy-propionamide, and
N-hydroxy-3-[1-(3-naphthalene-2-yl-propyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide.

7 - 20. (Canceled)


21. (Previously presented) The pharmaceutical composition of claim 6, wherein said compound is N-hydroxy-3-[1-(2-naphthalene-2-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide.


22. (Canceled)

23. (Currently amended) A method of treatment for prostate cancer or uterine cervical cancer to produce a beneficial effect comprising; administering a compound represented by the following general formula (III), and ~~the a~~ pharmaceutically acceptable salt or ~~the an~~ isomer thereof, to a Mammal in need thereof ~~treatment of a cancer disease,~~



wherein

X is selected from the group consisting of a hydroxyl group, -NHOH, -NHOCH₂Ph,  and



R is selected from the group consisting of a ~~lower~~ C1-C5 alkyl group, ~~lower~~ C2-C5 alkenyl group, ~~lower~~ C2-C5 alkynyl group, ~~lower~~ C3-C5 allyl group ~~having C1 to C5 carbon atoms~~, a heterocyclic group and aromatic aryl group;

n is an integer of 1 to 5; and

dotted line (≡) means double bond.

24. (Previously presented) The method of Claim 23; wherein said R is selected from the group consisting of thiophenyl group, naphthyl group, pyrrolyl group, furyl group and biphenyl group.

25. (Previously presented) The method of Claim 24; wherein said compound is selected from the group consisting of;

N-hydroxy-3-(1-naphthalene-2-ylmethyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-propionamide,
N-hydroxy-3-(1-methyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-propionamide,
3-(1-allyl-2-oxo-2,5-dihydro-1H-pyrrol-3-yl)-N-hydroxy-propionamide,
N-hydroxy-3-[1-(2-naphthalene-1-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,
N-hydroxy-3-[1-(2-naphthalene-2-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,
N-hydroxy-3-[2-oxo-1-(2-thiophen-2-yl-ethyl)-2,5-dihydro-1H-pyrrol-3-yl]-propionamide,
3-[1-(3-biphenyl-4-yl-propyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-N-hydroxy-propionamide, and
N-hydroxy-3-[1-(3-naphthalene-2-yl-propyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide.

26. (Previously presented) The method of Claim 25; wherein said compound is N-hydroxy-3-[1-(2-naphthalene-2-yl-ethyl)-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-propionamide.

27 - 28. (Canceled)